By Fineline Cube 
Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year levels, with group sales of €9.660 billion (≈ US$11.19 billion) and EBITDA before special items up 20.8 % to €1.511 billion (≈ US$1.75 billion) on a currency‑ and portfolio‑adjusted basis.
Financial Highlights
| Metric | 2025Q3 | YoY % |
|---|---|---|
| Group sales (Fx‑adj.) | €9.660 bn | +0.9 % |
| EBITDA before special items | €1.511 bn | +20.8 % |
| Pharmaceuticals sales | €4.335 bn | +0.4 % |
| Consumer Health sales | €1.415 bn | +2.0 % |
Pharmaceuticals Segment
| Sub‑segment | 2025Q3 sales (€bn) | YoY % |
|---|---|---|
| Nubeqa (prostate cancer) | 0.56 | +56.2 % |
| Kerendia (CKD + T2DM + HF) | 0.82 | +85.4 % |
| Mirena (contraceptives) | 0.18 | +22.9 % |
| Radiology (Ultravist & CT Fluid) | 0.25 | +18.3 % |
| Xarelto (oral anticoagulant) | 0.28 | –31.4 % |
| Eylea (ophthalmology) | 0.22 | –11.2 % |
Key takeaways:
- Nubeqa and Kerendia are the cornerstone drivers of the pharmaceutical upswing, posting double‑digit revenue increases.
- The Radiology portfolio rebounded strongly thanks to higher volumes and revised pricing for Ultravist and CT Fluid Delivery.
- Xarelto and Eylea experienced declines, largely attributable to patent expirations and generics competition, respectively.
Consumer Health Segment
| Category | 2025Q3 sales (€bn) | YoY % |
|---|---|---|
| Dermatology | 0.22 | +7.0 % |
| Digestive Health | 0.20 | +6.5 % |
| Pain & Cardio | 0.18 | +6.5 % |
| Allergy & Cold | 0.07 | –7.8 % |
Insights:
- Growth remained modest, constrained by a challenging retail outlook in North America and Asia/Pacific.
- Upward momentum in Dermatology, Digestive Health, and Pain & Cardio categories offset a decline in the Allergy & Cold segment.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Bayer’s financial performance, product‑level growth, and market dynamics. Actual results may differ materially because of regulatory, competitive, or other risks.-Fineline Info & Tech